Study assessments
Tumour, Cancer
DISEASE PROGRESSION, DISEASE, TUMOUR, CANCER
Disease assessment by CT scan will be performed at baseline and every 8 weeks, regardless of delays in drug administration until disease progression. QOL questionnaire (European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-STO22) will be completed at baseline and every 4 weeks during treatment and at the time of disease progression. For participants who end treatment before disease progression, QOL questionnaire will be collected every 8 weeks during follow up until disease progression. Tumour marker CA19-9 is assessed at the same time as CT imaging until disease progression.